Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions

REFERENCES

• Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991; 86(12):1601–1606.
   PubMedGoogle Scholar
• Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the Internet. Drug Alcohol Depend 2006; 83(Suppl. 1):S31–S39.
   PubMed Web of Science ®Google Scholar
• Katz NP, Buse DC, Budman SH, Wing VS, Fernandez KC, Benoit C, Bianchi R, Cooper D, Jasinski DR, Smith DE, Butler SF. Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Ind Pharm 2006; 32(6):727–746.
   PubMed Web of Science ®Google Scholar
• Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007; 23(8):648–660.
   PubMed Web of Science ®Google Scholar
• Savage S, Covington EC, Heit HA, Hunt J, Joranson D, Schnoll SH. Definitions related to the use of opioids for the treatment of pain. A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine, 2001. Available at: http://www.ampainsoc.org/advocacy/opioids2.htm. Last accessed on September 12, 2008.
   Google Scholar
• American Pain Society. The use of opioids for the treatment of chronic pain: consensus statement from American Academy of Pain Medicine and American Pain Society, 1996. Available at: http://www.ampainsoc.org/advocacy/opioids.htm. Last accessed on August 7, 2009.
   Google Scholar
• Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain 2008; 24(6):528–535.
   PubMed Web of Science ®Google Scholar
• Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006; 20(2):5–13.
   PubMedGoogle Scholar
• Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991; 13(1):1–23.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV, Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70(13):1657–1675.
   PubMed Web of Science ®Google Scholar
• Katz N Defining the prescription opioid abuse problem. Presented at the Joint Meeting of The Anesthetic and Life Support Drugs Advisory Committee and The Drug Safety and Risk Management Advisory Committee, November 14, 2008. Available at: http://www.fda.gov/ohrms/dockets/AC/cder08.html#DrugSafetyRiskMgmt. Last accessed on July 27, 2009.
   Google Scholar
• McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007; 32(3):562–575.
   PubMed Web of Science ®Google Scholar
• Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend 2008; 92(1–3):267–276.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Treatment admissions in urban and rural areas involving abuse of narcotic painkillers: 2002 update. August 6, 2004. Office of Applied Studies. The DASIS Report. Available at: http://www.oas.samhsa.gov/2k4/ruralPainTX/ruralPainTX.pdf. Last accessed on October 9, 2008.
   Google Scholar
• Villapiano A, Butler SF, Budman SH, Licari A, Morrison L, Lioy K, Houle B, Colucci R, Katz N. Demonstration of the feasibility of real-time, product-specific, prescription opioid abuse surveillance: The NAVIPPRO system, June 20, 2006. Annual Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
   Google Scholar
• Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, Magura S, Haddox JD. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90(1):64–71.
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J . National addictions vigilance intervention and prevention program (NAVIPPRO): A real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17(12):1142–1154.
   PubMed Web of Science ®Google Scholar
• Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69(2):175–181.
   PubMed Web of Science ®Google Scholar
• Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia – An update. Drug Alcohol Rev 2008; 27(2):197–199.
   PubMed Web of Science ®Google Scholar
• How to extract morphine powder from Kadian. 2009. Available at: http://www.bluelight.ru/vb/showthread.php?t=456652. Last accessed on September 15, 2009.
   Google Scholar
• Hays L, Kirsh KL, Passik SD. Seeking drug treatment for oxycontin abuse: A chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 2003; 1(3):423–428.
   PubMedGoogle Scholar
• Hays LR. A profile of OxyContin addiction. J Addict Dis 2004; 23(4):1–9.
   PubMed Web of Science ®Google Scholar
• Cone EJ. Recent discoveries in pharmacokinetics of drugs of abuse. Toxicol Lett 1998; 102–103:97–101.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National findings. DHHS Publication No. SMA 07-42932007. Rockville, MD. NSDUH Series H-32. Available at: http://www.oas.samhsa.gov/NSDUH/2K6NSDUH/2K6results.cfm. Last accessed on July 1, 2010.
   Google Scholar
• Colliver JD, Kroutil LA, Dai L, Gfroerer JC Misuse of prescription drugs: Data from the 2002, 2003, and 2004 National Surveys on Drug Use and Health. DHHS Publication No. SMA 06-4192, Analytic Series A-282006. Rockville, MD, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Available at http://www.oas.samhsa.gov/prescription/toc.htm. Last accessed on October 9, 2008.
   Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR, Jr., Green J, Rumack BH, Heard SE. 2006 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS). Clin Toxicol (Phila) 2007; 45(8):815–917.
   Web of Science ®Google Scholar
• Center for Substance Abuse Research. One-half of US oxycodone-related deaths related to OxyContin. CESAR Fax 2002; 11(21). University of Maryland, College Park.
   Google Scholar
• Tharp AM, Winecker RE, Winston DC. Fatal intravenous fentanyl abuse: Four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol 2004; 25(2):178–181.
   PubMed Web of Science ®Google Scholar
• Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35(7):513–516.
   PubMed Web of Science ®Google Scholar
• Kintz P. Deaths involving buprenorphine: A compendium of French cases. Forensic Sci Int 2001; 121(1–2):65–69.
   PubMed Web of Science ®Google Scholar
• Abate R. Reported manipulation of oxycodone extended-release tablets and morphine extended-release products. Presented at the Joint Meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees. November 13, 2008. Available at: http://www.fda.gov/ohrms/dockets/AC/08/slides/2008-4395s1-01-FDA-Abate_files/frame.htm. Last accessed on July 27, 2009.
   Google Scholar
• Greene D. Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat J 2005; 84(8):512, 514, 516.
   PubMedGoogle Scholar
• Jewers WM, Rawal YB, Allen CM, Kalmar JR, Fox E, Chacon GE, Sedghizadeh PP. Palatal perforation associated with intranasal prescription narcotic abuse. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99(5):594–597.
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005; 11:469–479.
   PubMedGoogle Scholar
• Arnett EN, Battle WE, Russo JV, Roberts WC. Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 1976; 60(5):711–718.
   Google Scholar
• Tomashefski JF, Jr., Hirsch CS. The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 1980; 11(2):133–145.
   Google Scholar
• Pare JA, Fraser RG, Hogg JC, Howlett JG, Murphy SB. Pulmonary ‘mainline’ granulomatosis: Talcosis of intravenous methadone abuse. Medicine (Baltimore) 1979; 58(3):229–239.
   Google Scholar
• de Lima MA, dos Santos V, Demachki S, Lazo J. Titanium pigment in tissues of drug addicts: Report of 5 necropsied cases. Rev Hosp Clin Fac Med Sao Paulo 2004; 59(2):86–88.
   Google Scholar
• Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: What is their role in addressing prescription opioid abuse? CNS Drugs 2010; 24(10):805–810.
   PubMed Web of Science ®Google Scholar
• Hamed E, Moe D. Development of tamper deterrent formulations: State of the pharmaceutical industry. Curr Drug Abuse Rev 2010; 3(3):139–46. Epub ahead of print.
   Google Scholar